Risk Prediction for Development of Adverse Effects FOllowing Radiotherapy for Prostate Cancer

前列腺癌放疗后发生不良反应的风险预测

• 批准号: 9146319
• 负责人: Sarah L. Kerns
• 金额: $ 12.99万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-18 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9146319
• 关键词: Adjuvant; Adverse effects; Affect; Age; American; Androgens; Area; Award; Biological; Biology; Cancer Biology; Cancer Patient; Cancer Survivor; Cell Proliferation; Clinical; Clinical Trials Design; Collaborations; Comorbidity; Complement; Complication; Cytokine Signaling; Data; Data Analyses; Data Set; Databases; Development; Diabetes Mellitus; Diagnosis; Dose; Educational workshop; Ensure; Environment; Erectile dysfunction; Funding; Genes; Genetic; Genetic screening method; Genotype; Goals; Gold; Guidelines; Health; Health Personnel; Hormones; Hypertension; Individual; Institutes; Intestines; Late Effects; Lead; Left; Malignant Neoplasms; Malignant neoplasm of prostate; Manuscripts; Medical center; Mentors; Mentorship; Meta-Analysis; Modeling; Normal tissue morphology; Odds Ratio; Operative Surgical Procedures; Outcome; Outcomes Research; Pathway interactions; Patient Recruitments; Patients; Performance; Physicians; Positioning Attribute; Probability; Process; Prospective Studies; Protocols documentation; Publishing; Quality of life; Radiation; Radiation Oncology; Radiation Tolerance; Radiation Toxicity; Radiation therapy; Radiobiology; Radiogenomics; Research; Research Activity; Research Design; Research Personnel; Resources; Risk; Risk Assessment; Risk Factors; Signal Transduction; Single Nucleotide Polymorphism; Societies; Staging; Statistical Models; Testing; Toxic effect; Training; Treatment outcome; Treatment-related toxicity; Universities; Validation; Work; anticancer research; base; cancer care; cancer diagnosis; cancer genetics; cancer therapy; career; clinical risk; clinically actionable; cohort; deprivation; experience; genetic association; genetic epidemiology; genetic predictors; genetic risk factor; genome wide association study; hormone therapy; improved; insight; interest; meetings; member; men; non-genetic; performance tests; predicting response; programs; prospective; radiation response; rectal; treatment planning; urinary

 DESCRIPTION (provided by applicant): My research and career focus is on predicting response to cancer treatment, with a specific concentration on adverse effects that negatively impact quality of life. I have been trained in cancer biology and genetic epidemiology, and my long-term career goal is to establish an NCI-supported independent research program focused on development and clinical implementation of genetic tests that predict for cancer treatment outcomes. My short-term research interests focus specifically on genetic predictors of response to radiation treatment. This area of research, termed 'radiogenomics', is an exciting, and relatively new field. The ultimate goal of this work is to develop a clinically useful genetic test that can stratify cancer patients as to their risk of developing adverse radiotherapy effects. Such a test could be used to provide information to individuals receiving a cancer diagnosis that will help them, along with their physician, choose the best course of treatment that will minimize adverse effects. This work has potential to significantly improve quality-of-life for millions of cancer survivors. My immediate goal within the context of this K07 award is to develop and test integrative risk models, based on genetic and non-genetic risk factors, for development of urinary, rectal and sexual adverse effects of radiotherapy used in treatment of prostate cancer. The proposed research aims to 1) develop risk models using the a large set of existing radiogenomics datasets, leveraging valuable resources of the NCI-supported Radiogenomics Consortium; and 2) test these risk models in an independent, prospective study conducted at the University of Rochester Wilmot Cancer Institute. The proposed study is expected to yield important results as well as provide additional experience and training needed to prepare me to embark on an independent career. My research activities will be complemented by mentorship, didactic coursework and attendance of workshops and national meetings. I have assembled an outstanding mentor team comprised of leaders in clinical cancer research, radiation biology and oncology, and prostate cancer. The University of Rochester Medical Center and Wilmot Cancer Institute provide an outstanding environment in which to perform this important work and train to become a leader in clinical translational cancer research.

 描述（由应用程序提供）：我的研究和职业重点是预测对癌症治疗的反应，特别关注对生活质量的不利影响。我已经接受过癌症生物学和遗传流行病学的培训，我的长期职业目标是建立一个由NCI支持的独立研究计划，重点是开发和临床实施基因测试，以预测癌症治疗结果。我的短期研究兴趣专门集中于对放射治疗反应的遗传预测指标。这一称为“放射基因组学”的研究领域是一个令人兴奋且相对较新的领域。这项工作的最终目标是开发临床上有用的基因检测 这可以使癌症患者患有不良放射疗法影响的风险。这样的 一项测试可用于向接受癌症诊断的个体提供信息，这将帮助他们以及他们的物理学选择最佳的治疗方法，以最大程度地减少不良影响。这项工作有可能显着改善数百万癌症生存的生活质量。在该K07奖的背景下，我的直接目标是基于遗传和非遗传风险因素开发和测试整合风险模型，用于开发用于治疗前列腺癌的放射治疗的尿，直肠和性不良影响。拟议的研究目的是1）使用大量现有的放射基因组学数据集开发风险模型，利用NCI支持的放射基因组学财团的宝贵资源； 2）在罗切斯特·威尔莫特癌症研究所（Rochester Wilmot Cancer Institute）进行的一项独立的前瞻性研究中测试这些风险模型。拟议的研究预计将产生重要的结果，并提供其他经验和培训，以使我开始从事独立职业。我的研究活动将通过Mentalship，Dactic课程以及研讨会和国家会议的出席来完成。我组建了一个杰出的心理团队，完成了临床癌症研究，放射生物学和肿瘤学以及前列腺癌领域的领导者。罗切斯特大学医学中心和威尔莫特癌症研究所提供了一个杰出的环境，在该环境中，进行这项重要工作和训练成为临床转化癌症研究的领导者。